ArticleScientific reports2019
Transcriptome profiling-based identification of prognostic subtypes and multi-omics signatures of glioblastoma.
Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Tracing the origins of glioblastoma by investigating the role of gliogenic and related neurogenic genes/signaling pathways in GBM development: a systematic review.World journal of surgical oncology · 2022Pooled it
- Article
- Enhancer of Zeste Homolog 2 (EZH2): From Glioblastoma Biology to Potential Epigenetic Therapy.International journal of molecular sciences · 2026Review
- Machine learning model on multi-omics data enables risk stratification and identifies molecular heterogeneity and therapeutic targets in glioblastoma.Molecular cancer · 2026Article
- Identification of Tumor- and Immunosuppression-Driven Glioblastoma Subtypes Characterized by Clinical Prognosis and Therapeutic Targets.Current issues in molecular biology · 2026Article
- From Data to Decision: Integrating Bioinformatics into Glioma Patient Stratification and Immunotherapy Selection.International journal of molecular sciences · 2026Review
- A novel tumor microenvironment-related gene signature for prognostic prediction of intrahepatic cholangiocarcinoma.Scientific reports · 2025Article
- Artificial Intelligence-Driven Multi-Omics Approaches in Glioblastoma.International journal of molecular sciences · 2025Review
- Artificial intelligence in precision medicine: transforming disease subtyping, medical imaging, and pharmacogenomics.Emerging topics in life sciences · 2025Article
- Tumor microenvironment-preserving gliosarcoma organoids as an in vitro preclinical platform: a comparative analysis with glioblastoma models.Journal of translational medicine · 2025Article
- Robust Cluster Prediction Across Data Types Validates Association of Sex and Therapy Response in GBM.Cancers · 2025Article
- Identification and Validation of Prognostic Genes Related to Histone Lactylation Modification in Glioblastoma: An Integrated Analysis of Transcriptome and Single-cell RNA Sequencing.Journal of Cancer · 2025Article
- GDNF/GFRA1 signaling contributes to chemo- and radioresistance in glioblastoma.Scientific reports · 2024Article
- Comparison of Glioblastoma Cell Culture Platforms Based on Transcriptional Similarity with Paired Tissue.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Methods for multi-omic data integration in cancer research.Frontiers in genetics · 2024Review
- Classification of IDH wild-type glioblastoma tumorspheres into low- and high-invasion groups based on their transcriptional program.British journal of cancer · 2023Article
- C5α secreted by tumor mesenchymal stem-like cells mediates resistance to 5-aminolevulinic acid-based photodynamic therapy against glioblastoma tumorspheres.Journal of cancer research and clinical oncology · 2023Article
- The Role of a Lung Vascular Endothelium Enriched Gene TMEM100.Biomedicines · 2023Review
- Mesenchymal Stem-Like Cells Derived from the Ventricle More Effectively Enhance Invasiveness of Glioblastoma Than Those Derived from the Tumor.Yonsei medical journal · 2023Article
- A Novel Molecular Classification Method for Glioblastoma Based on Tumor Cell Differentiation Trajectories.Stem cells international · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is a lethal tumor, but few biomarkers and molecular subtypes predicting prognosis are available. This study was aimed to identify prognostic subtypes and multi-omics signatures for GBM. Using oncopression and TCGA-GBM datasets, we identified 80 genes most associated with GBM prognosis using correlations between gene expression levels and overall survival of patients. The prognostic score of each sample was calculated using these genes, followed by assigning three prognostic subtypes. This classification was validated in two independent datasets (REMBRANDT and Severance). Functional annotation revealed that invasion- and cell cycle-related gene sets were enriched in poor and favorable group, respectively. The three GBM subtypes were therefore named invasive (poor), mitotic (favorable), and intermediate. Interestingly, invasive subtype showed increased invasiveness, and MGMT methylation was enriched in mitotic subtype, indicating need for different therapeutic strategies according to prognostic subtypes. For clinical convenience, we also identified genes that best distinguished the invasive and mitotic subtypes. Immunohistochemical staining showed that markedly higher expression of PDPN in invasive subtype and of TMEM100 in mitotic subtype (P < 0.001). We expect that this transcriptome-based classification, with multi-omics signatures and biomarkers, can improve molecular understanding of GBM, ultimately leading to precise stratification of patients for therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.